These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12071779)

  • 41. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R; Layton D; Harris S; Wilton L; Shakir SA
    Drug Saf; 2005; 28(9):803-16. PubMed ID: 16119973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
    Clark RC; Maxwell SR; Kerr S; Cuthbert M; Buchanan D; Steinke D; Webb DJ; Bateman ND
    Drug Saf; 2007; 30(4):357-66. PubMed ID: 17408312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
    Kasliwal R; Wilton LV; Cornelius V; Aurich-Barrera B; Shakir SA
    Drug Saf; 2007; 30(2):157-70. PubMed ID: 17253880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
    Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The way towards adverse event monitoring in clinical trials.
    Wallander MA
    Drug Saf; 1993 Mar; 8(3):251-62. PubMed ID: 8452665
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
    Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
    Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.
    Aurich-Barrera B; Wilton L; Harris S; Shakir SA
    Drug Saf; 2006; 29(2):151-60. PubMed ID: 16454542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statistical techniques for signal generation: the Australian experience.
    Purcell P; Barty S
    Drug Saf; 2002; 25(6):415-21. PubMed ID: 12071778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.
    Hazell L; Cornelius V; Wilton LV; Shakir SA
    BJU Int; 2009 Feb; 103(4):506-14. PubMed ID: 18990133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management.
    Layton D; Hazell L; Shakir SA
    Drug Saf; 2011 Dec; 34(12):e1-9. PubMed ID: 22077508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prescription-event monitoring--recent progress and future horizons.
    Mann RD
    Br J Clin Pharmacol; 1998 Sep; 46(3):195-201. PubMed ID: 9764958
    [No Abstract]   [Full Text] [Related]  

  • 58. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.